This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Pharma Stocks With 100% Buy Ratings

8. Athersys (ATHX - Get Report) is a clinical-stage biopharmaceutical company engaged in the discovery and development of therapeutic drugs.

For 2010 fourth quarter, analysts polled by Bloomberg expect the company to report a loss of 18 cents per share, against a loss of 19 cents reported in the quarter-ago period. For full year 2010, the company is seen reporting a loss per share of 68 cents and 59 cents for 2011.

The stock will likely provide an upside of 156% over the next 12 months with a consensus target price of $6.5, according to analysts polled by Bloomberg. Conversely, Celgene (CELG), Genzyme (GENZ), Osiris Therapeutics (OSIR), Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX) are likely to return around 31%, 4%, -15%, -34% and -19%, respectively.

All the four analysts covering the stock recommend buying.
4 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PATH $0.00 0.00%
BDSI $3.73 0.00%
ATHX $1.23 0.00%
CPHI $0.14 0.00%
MNOV $4.15 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs